Dosimetry and treatment planning of Occu-Prosta I-125 seeds for intraocular lesions
- PMID: 20041047
- PMCID: PMC2786092
- DOI: 10.4103/0971-6203.39419
Dosimetry and treatment planning of Occu-Prosta I-125 seeds for intraocular lesions
Abstract
Intraocular malignant lesions are frequently encountered in clinical practice. Plaque brachytherapy represents an effective means of treatment for intraocular lesions. Recently Radiopharmaceutical Division, BARC, Mumbai, has indigenously fabricated reasonable-cost I-125 sources. Here we are presenting the preliminary experience of dosimetry of sources, configuration of treatment planning system (TPS) and quality assurance (QA) for eye plaque therapy with Occu-Prosta I-125 seeds, treated in our hospital, for a patient with ocular lesions. I-125 seeds were calibrated using well-type chamber. BrachyVision TPS was configured with Monte Carlo computed radial dose functions and anisotropy functions for I-125 sources. Dose calculated by TPS at different points in central axis and off axis was compared with manually calculated dose. Eye plaque was fabricated of 17 karat pure gold, locally. The seeds were arranged in an outer ring near the edge of the plaque and in concentric rings throughout the plaque. The sources were manually digitized on the TPS, and dose distribution was calculated in three dimensions. Measured activity using cross-calibrated well-type chamber was within +/-10% of the activity specified by the supplier. Difference in TPS-calculated dose and manually calculated dose was within 5%. Treatment time calculated by TPS was in concordance with published data for similar plaque arrangement.
Keywords: I-125; dosimetry and planning; eye plaque; intraocular lesions.
Conflict of interest statement
Figures





Similar articles
-
Comparison of dose calculation methods for brachytherapy of intraocular tumors.Med Phys. 2011 Jan;38(1):306-16. doi: 10.1118/1.3523614. Med Phys. 2011. PMID: 21361199 Free PMC article.
-
Validation of American Association of Physicists in Medicine TG 43 Dosimetry Data in Commercial Treatment Planning System.J Med Phys. 2021 Jul-Sep;46(3):197-203. doi: 10.4103/jmp.JMP_20_21. Epub 2021 Sep 8. J Med Phys. 2021. PMID: 34703104 Free PMC article.
-
Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.Med Phys. 2012 Oct;39(10):6161-84. doi: 10.1118/1.4749933. Med Phys. 2012. PMID: 23039655
-
An approach to using conventional brachytherapy software for clinical treatment planning of complex, Monte Carlo-based brachytherapy dose distributions.Med Phys. 2009 Jun;36(6):1968-75. doi: 10.1118/1.3121510. Med Phys. 2009. PMID: 19610285
-
Dosimetric verification of a dedicated 3D treatment planning system for episcleral plaque therapy.Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):1159-66. doi: 10.1016/s0360-3016(01)01768-0. Int J Radiat Oncol Biol Phys. 2001. PMID: 11704341
Cited by
-
Episcleral plaque brachytherapy using 'BARC I-125 Ocu-Prosta seeds' in the treatment of intraocular tumors: a single-institution experience in India.Indian J Ophthalmol. 2012 Jul;60(4):289-95. doi: 10.4103/0301-4738.98708. Indian J Ophthalmol. 2012. PMID: 22824598 Free PMC article.
-
A Retrospective Study on Using a Novel Single Needle Cone Puncture Approach for the Iodine-125 Seed Brachytherapy in Treating Patients With Thoracic Malignancy.Front Oncol. 2021 May 31;11:640131. doi: 10.3389/fonc.2021.640131. eCollection 2021. Front Oncol. 2021. PMID: 34136382 Free PMC article.
References
-
- Freire JE, De Potter P, Brady LW, Longton WA. Brachytherapy in primary ocular tumors. Semin Surg Oncol. 1997;13:167–76. - PubMed
-
- Char DH, Quivey JR, Castro JR, Kroll S, Phillips T. Helium ions versus I-125 plaque therapy in the management of uveal melanoma: A prospective, randomized, dynamically balanced trial. Ophthalmology. 1993;100:1547–54. - PubMed
-
- Nag S, Quivey JM, Earle JD, Followill D, Fontanesi J, Finger PT, et al. The American brachytherapy society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys. 2003;56:544–55. - PubMed
-
- Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, et al. The COMS randomized trial of Iodine-125 brachytherapy for choroidal melanoma, III: Initial mortality findings. Arch Ophthalmol. 2001;119:969–82. - PubMed
-
- Melia BM, Abramson DH, Albert DM, Boldt HC, Earle JD, Hanson WF, et al. Collaborative Ocular Melanoma Study Randomized Trial of I-125 brachytherapy for medium choroidal melanoma, I. Visual acuity after 3 years: COMS Report No 16. Ophthalmology. 2001;108:348–66. - PubMed